Livers of MASLD Patients End Up Less Fatty With Novel Injectable

(MedPage Today) — WASHINGTON — A large percentage of people with metabolic dysfunction-associated steatotic liver disease (MASLD) had their liver fat content normalize with an investigational dual agonist of the GLP-1 and glucagon receptors…

Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118499

Author :

Publish date : 2025-11-13 15:53:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Livers of MASLD Patients End Up Less Fatty With Novel Injectable

U.S. Bishops Officially Ban Gender-Affirming Care at Catholic Hospitals

Ultraprocessed Foods Tied to Early Colorectal Adenoma Risk

Related Posts

Hearing in Luigi Mangione’s State Murder Case Sheds New Light on His Arrest

At-Home HPV Sampling Endorsed in ACS Cervical Cancer Screening Guidelines

‘Freebirth’ Movement Is Dangerous to Moms but Reflects Real Concerns, Ob/Gyns Say

Ultrasound Can Aid Treatment of Vascular Complications From Cosmetic Fillers

How Wi-Fi Could Become an Invisible, No-Touch ECG

COVID Shots Tied to a Lower Risk of Death From Any Cause

Hearing in Luigi Mangione’s State Murder Case Sheds New Light on His Arrest

At-Home HPV Sampling Endorsed in ACS Cervical Cancer Screening Guidelines

‘Freebirth’ Movement Is Dangerous to Moms but Reflects Real Concerns, Ob/Gyns Say

Ultrasound Can Aid Treatment of Vascular Complications From Cosmetic Fillers

How Wi-Fi Could Become an Invisible, No-Touch ECG

COVID Shots Tied to a Lower Risk of Death From Any Cause

CDC Advisors Delay Hepatitis B Vaccine Vote Again

Cell-Free DNA Blood Test Shows Promise in CRC Screening

Categories

Archives